This population-based study shows that shared and pattern-specific blood biomarkers reflect biological vulnerability ...

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics ...

Staying on top of your health isn’t just about hitting the gym, eating well, or getting the necessary vaccines. It also means ...

Possible Reasons, and The Best Labs for Fatigue Key Takeaways: Fatigue describes more than just feeling sleepy — it’s a ...

An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...

AB Science receives US patent for masitinib to treat sickle cell disease: Paris Friday, December 26, 2025, 14:00 Hrs [IST] AB Science SA, a pharmaceutical company specializing in ...

Doctors associate ongoing lightheadedness with circulation issues, heart rhythm changes, blood pressure instability, or inner ...

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and ...